Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
05 déc. 2021 18h47 HE
|
Mesoblast Limited
Key points: Analysis of pre-specified high-risk groups in the DREAM-HF Phase 3 trial of rexlemestrocel-L in patients with chronic heart failure and low ejection fraction (HFrEF) showed greatest...
Operational Highlights and Financial Results for the Period Ended September 30, 2021
23 nov. 2021 18h09 HE
|
Mesoblast Limited
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
Mesoblast Corporate Update and Financial Results Webcast
23 nov. 2021 07h18 HE
|
Mesoblast Limited
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
21 nov. 2021 19h31 HE
|
Mesoblast Limited
NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has...
Late Breaking Presentation at American Heart Association Annual Meeting of Landmark Phase 3 Trial of Rexlemestrocel-L in Chronic Heart Failure
14 nov. 2021 19h13 HE
|
Mesoblast Limited
Trial Results Highlighted Reduction in Cardiovascular Mortality, Heart Attacks and Strokes, with Greatest Effect Seen in Setting of Inflammation NEW YORK, Nov. 14, 2021 (GLOBE NEWSWIRE) --...
Appendix 4C Quarterly Activity Report
28 oct. 2021 19h51 HE
|
Mesoblast Limited
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Remestemcel-L Improves Survival of Children With Biomarkers for Highest Mortality in Steroid Refractory Acute GVHD
18 oct. 2021 08h00 HE
|
Mesoblast Limited
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results published...
Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart Failure Selected as Late Breaking Presentation at American Heart Association Annual Meeting
06 oct. 2021 20h38 HE
|
Mesoblast Limited
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the...
Operational Highlights and Financial Results for the Year Ended June 30, 2021
30 août 2021 19h38 HE
|
Mesoblast Limited
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights...
Mesoblast Corporate Update and Financial Results Webcast
30 août 2021 08h00 HE
|
Mesoblast Limited
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...